HC Wainwright Reiterates “Neutral” Rating for Xenetic Biosciences (NASDAQ:XBIO)

Xenetic Biosciences (NASDAQ:XBIO)‘s stock had its “neutral” rating reissued by equities researchers at HC Wainwright in a report released on Friday,Benzinga reports.

Xenetic Biosciences Trading Up 2.3 %

NASDAQ:XBIO opened at $4.11 on Friday. Xenetic Biosciences has a 12 month low of $2.78 and a 12 month high of $5.20. The company has a 50-day moving average price of $3.91 and a 200-day moving average price of $3.92. The stock has a market cap of $6.32 million, a price-to-earnings ratio of -1.54 and a beta of 2.25.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). The firm had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.75 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. Equities analysts forecast that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.